Clinical trial design among areas regulators will collaborate on
Aims to recruit 4,900 patients to prove value in heart failure
This week’s news
NeuroEyeCoach helps users re-train their eye movement to better compensate for visual field loss.
Candidate takes novel approach to targeting DNA damage response
BMS and Nektar’s combination latest in frenzied immunotherapy field
Chief executive Steve Harris confident company can bounce back
NVIDIA’s DGX-1 will help generate research insights.
Company will remain as one, but Read keeps his options open
Drug could earn $2.8 billion if approved in AD and asthma
App will track activity levels to improve intervention and treatment of condition.
Amgen’s biosimilar is ready to go, but AbbVie believes it can delay until 2022
Trial’s next phase will recruit 3,000 patients across 21 international sites.